癌症是本世紀最具挑戰的議題，此疾病擁有高致死率以及不佳的癒後效果，現階段臨床常見的治療方式包括了手術、放射療法、化療、免疫療法以及標靶治療。然而，現今的治療策略沒有辦法有效的選擇性作用至癌症位置，且有較差的副作用。
奈米藥物擁有高滲透滯留效應，將奈米粒子有效運用在藥物輸送系統能顯著改善副作用、增進療效。現今，奈米藥物開發著重在研發出具有隱身性質的奈米用藥以運用在疾病治療上，聚乙烯二醇是常見的奈米藥物表面修飾的生醫材料，其具有優良的生物相容性，能增加奈米載體血中循環且降低免疫細胞捕捉。然而，聚乙烯二醇近年來有多篇研究證明其具有誘導身體產生抗聚乙烯二醇抗體，在漢族群中有超過44.3%以具有內生性的抗體，可能來自接觸生活中的聚乙烯二醇製品(牙膏、沐浴乳等)或是接受過含聚乙烯二醇藥劑治療。再者，過去研究發現豬的動物模型中，當存在抗聚乙烯二醇抗體時，打入由聚乙烯二醇表面修飾的脂質體時，會出現致死性的輸注性過敏反應，療效也跟著降低。本研究主旨於建立短練的聚乙烯二醇修飾的奈米藥物，使用的奈米包括脂質體、多孔洞矽奈米、金奈米，探討長鏈與短練的聚乙烯二醇在療效與副作用上的差異性，並且提出一個藥物篩選系統以為未來的聚乙烯二醇修飾藥物鋪墊藥物快篩基礎。

Cancer is the challenging issue for modern medicine development, with the leading morality rate and poor therapeutic response. Common treatment includes surgery, radiation, chemotherapy, immunotherapy and target therapy. However, current cancer treatments are restricted for poor targeting selectivity and worse adverse reactions.
Thanks to the EPR effect (enhanced permeability and retention effect), the application of nanotechnology in drug delivery systems has given significant impacts on the pharmaceutical industry. Nowadays, the most widely used modification belongs to polyethylene glycol (PEG), which is also the gold standard for stealth functionality. PEG has the advantage to prolong nanoparticle circulation and escape from immune capture. However, based on previous research, Taiwanese were detected about 44.3% of pre-existing anti-PEG antibodies, which might have risen by exposure with PEG products or pharmaceuticals. To this point, Janos Szebeni's team demonstrated a lethal immune reaction after treatment with PEGylated liposome under pre-existing anti-PEG antibodies. Also, therapeutic outcomes declined under such conditions. The overriding objective in this project is to engineer a short-chain/brush PEG-grafted nanoparticles, including liposomes, mesoporous silica nanoparticles (MSN), gold nanoparticles (GNP) for promoting therapeutic effects and avoiding immune response. Also, to compare different length PEG-coating property, we applied engineering PEGylated nanoparticles in therapeutic outcome evaluation and safety monitoring. Drug screening platform was built for next-generation nanoparticle immune prediction.

1. Bros, M., et al., The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery. Frontiers in Immunology, 2018. 9(1760).
2. Harris, J.M., N.E. Martin, and M. Modi, Pegylation. Clinical Pharmacokinetics, 2001. 40(7): p. 539-551.
3. Harris, J.M. and R.B. Chess, Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery, 2003. 2(3): p. 214-221.
4. Lee, C.-C., et al., Structural basis of polyethylene glycol recognition by antibody. Journal of Biomedical Science, 2020. 27(1): p. 12.
5. Chapman, R.G., et al., Surveying for Surfaces that Resist the Adsorption of Proteins. Journal of the American Chemical Society, 2000. 122(34): p. 8303-8304.
6. Kozma, G.T., et al., Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Advanced Drug Delivery Reviews, 2020. 154-155: p. 163-175.
7. Turecek, P.L., et al., PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. Journal of Pharmaceutical Sciences, 2016. 105(2): p. 460-475.
8. Lee, H., Molecular Simulations of PEGylated Biomolecules, Liposomes, and Nanoparticles for Drug Delivery Applications. Pharmaceutics, 2020. 12(6): p. 533.
9. Walkey, C.D., et al., Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake. Journal of the American Chemical Society, 2012. 134(4): p. 2139-2147.
10. Yang, Q., et al., Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol Pharm, 2014. 11(4): p. 1250-8.
11. Suzuki, T., et al., Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. International Journal of Pharmaceutics, 2012. 436(1): p. 636-643.
12. Hsieh, Y.-C., et al., Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Theranostics, 2018. 8(11): p. 3164-3175.
13. Richter, A.W. and E. Akerblom, Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol, 1983. 70(2): p. 124-31.
14. Wang, X., T. Ishida, and H. Kiwada, Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. Journal of Controlled Release, 2007. 119(2): p. 236-244.
15. Mima, Y., et al., Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein. Molecular Pharmaceutics, 2015. 12(7): p. 2429-2435.
16. Ishida, T. and H. Kiwada, Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. International Journal of Pharmaceutics, 2008. 354(1): p. 56-62.
17. Levinson, W., et al., Chapter 65: Hypersensitivity (Allergy), in Review of Medical Microbiology & Immunology: A Guide to Clinical Infectious Diseases. 2018, McGraw-Hill Education.
18. Lake, D.F. and A.D. Briggs, Chapter 55: Immunopharmacology, in Basic & Clinical Pharmacology, 15e. 2021, McGraw-Hill Education.
19. Yazdany, J., et al., 20-54: Immediate Hypersensitivity, in Current Medical Diagnosis & Treatment 2021. 2021, McGraw Hill Education.
20. Jameson, J.L., et al., Chapter 159: Diseases of Immediate-Type Hypersensitivity, in Harrison's Manual of Medicine, 20e. 2020, McGraw-Hill Education.
21. Luskin, A.T. and S.S. Luskin, Anaphylaxis and Anaphylactoid Reactions: Diagnosis and Management. Am J Ther, 1996. 3(7): p. 515-520.
22. Yunginger, J.W., Anaphylaxis. Curr Probl Pediatr, 1992. 22(3): p. 130-46; discussion 147.
23. Szebeni, J., Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology, 2005. 216(2): p. 106-121.
24. Szebeni, J., Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals. Molecular Immunology, 2014. 61(2): p. 163-173.
25. Rüggeberg, J.U., et al., Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2007. 25(31): p. 5675-5684.
26. de Vrieze, J., Pfizer's vaccine raises allergy concerns. Science, 2021. 371(6524): p. 10.
27. Merle, N.S., et al., Complement System Part I – Molecular Mechanisms of Activation and Regulation. Frontiers in Immunology, 2015. 6(262).
28. Merle, N.S., et al., Complement System Part II: Role in Immunity. Frontiers in Immunology, 2015. 6(257).
29. Lo, M.W. and T.M. Woodruff, Complement: Bridging the innate and adaptive immune systems in sterile inflammation. Journal of Leukocyte Biology, 2020. 108(1): p. 339-351.
30. Morgan, B.P. and C.L. Harris, Complement, a target for therapy in inflammatory and degenerative diseases. Nature Reviews Drug Discovery, 2015. 14(12): p. 857-877.
31. Chen, E., et al., Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex. ACS Nano, 2020. 14(7): p. 7808-7822.
32. Szebeni, J., et al., Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles. Journal of Liposome Research, 2007. 17(2): p. 107-117.
33. Szebeni, J., et al., Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. American Journal of Physiology-Heart and Circulatory Physiology, 2006. 290(3): p. H1050-H1058.
34. Kozma, G.T., et al., Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions. ACS Nano, 2019. 13(8): p. 9315-9324.
35. Global Cancer Observatory: Cancer Today. . [cited 2021 June 20]; Available from: https://gco.iarc.fr/.
36. Harbeck, N., et al., Breast cancer. Nature Reviews Disease Primers, 2019. 5(1): p. 66.
37. Waks, A.G. and E.P. Winer, Breast Cancer Treatment: A Review. JAMA, 2019. 321(3): p. 288-300.
38. National Comprehensive Cancer Network. Breast Cancer (Version 6.2020). November 24, 2020]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
39. Loibl, S., et al., Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. The Lancet Oncology, 2018. 19(4): p. 497-509.
40. Litton, J.K., et al., Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine, 2018. 379(8): p. 753-763.
41. Rahman, A.M., S.W. Yusuf, and M.S. Ewer, Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. International journal of nanomedicine, 2007. 2(4): p. 567-583.
42. He, H., et al., Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs. Pharmaceutics, 2019. 11(3): p. 110.
43. Ewer, M.S., et al., Cardiac safety of liposomal anthracyclines. Seminars in Oncology, 2004. 31: p. 161-181.
44. Fukuda, A., et al., Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLOS ONE, 2017. 12(9): p. e0185654.
45. O’Brien, M.E.R., et al., Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Annals of Oncology, 2004. 15(3): p. 440-449.
46. Waterhouse, D.N., et al., A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form. Drug Safety, 2001. 24(12): p. 903-920.
47. Wu, S.-H., Y. Hung, and C.-Y. Mou, Mesoporous silica nanoparticles as nanocarriers. Chemical Communications, 2011. 47(36): p. 9972-9985.
48. Lewrick, F. and R.P. Süss, Remote loading of anthracyclines into liposomes, in liposome methods and protocols, S.C. Basu and M. Basu, Editors. 2010, Humana Press.
49. Makhsin, S.R., et al., The effects of size and synthesis methods of gold nanoparticle-conjugated MαHIgG4for use in an immunochromatographic strip test to detect brugian filariasis. Nanotechnology, 2012. 23(49): p. 495719.
50. Shah, M., et al., Gold nanoparticles: various methods of synthesis and antibacterial applications. Frontiers in bioscience, 2014. 19: p. 1320-44.
51. Tisoncik, J.R., et al., Into the eye of the cytokine storm. Microbiology and Molecular Biology Reviews, 2012. 76(1): p. 16-32.
52. Chen, B.-M., et al., Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Analytical Chemistry, 2016. 88(21): p. 10661-10666